Value of new, costly hepatitis drugs rides on SVR, experts say

02/19/2014 | MedPage Today (free registration)

The high price for new hepatitis drugs has drawn attention and experts say the key to determining whether treatments are worth the cost is the rate of sustained virologic response. Researcher Andrea Branch at Mount Sinai Hospital in New York City is monitoring the new drugs and may have some answers later this year, but she says for hepatitis C patients a cure can be priceless. University of Chicago Medical Center's Nancy Reau says the bottom line is more simple: "People with hep C cost money."

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY